medicament as disclosed herein, configured to locally administer the gemcitabine into the bladder continuously over a period of at least 6 hours, when the drug delivery device is to be inserted into the bladder. In another example, there is disclosed a drug delivery device comprising a medicament as disclosed herein, configured to release the gemcitabine when the drug delivery device is inserted into the bladder. In a further aspect, the present invention refers to a medical device comprising: a housing configured for intravesical insertion; and a dosage form comprising gemcitabine, wherein the housing holds the dosage form and is configured to release the gemcitabine into the bladder in an amount therapeutically effective for the treatment of prostate cancer, wherein the device is configured to release gemcitabine into the bladder at a mean average amount of from 1 mg/day to 300 mg/day of the gemcitabine, and wherein the device is configured to release gemcitabine into the bladder continuously over a period of over 6 hours. In another example, a medical device is disclosed for intravesical administration of gemcitabine. In an example, the medical device includes a housing configured for intravesical insertion and a dosage form including gemcitabine, wherein the housing holds the dosage form and is configured to release the gemcitabine into the bladder in an amount therapeutically effective for the treatment of the prostate, and wherein the device is configured to

What is claimed is:

1. Use of gemcitabine in the manufacture of a medicament for the treatment of prostate cancer, wherein the medicament is to be locally administered into the bladder of a patient to achieve a sustained concentration of the medicament in the urine in the bladder sufficient to produce a therapeutic concentration of the medicament in the prostate,

   wherein the medicament is to be locally administered into the patient's bladder at a mean average amount of from 1 mg/day to 300 mg/day of the gemcitabine, and wherein the medicament is to be locally administered into the patient's bladder continuously over a period of over 6 hours.

2. The use of claim 1, wherein the medicament is to be administered into the bladder from an intravesical drug delivery device which continuously releases the medicament into the urine in the bladder over the period.

3. The use of claim 2, wherein the intravesical drug delivery device continuously releases the medicament into the urine in the bladder over a period of 1 day to 14 days.

4. The use of claim 2, wherein the intravesical drug delivery device comprises a housing which contains and controllably releases the medicament and is elastically deformable between a retention shape configured to retain the device in a patient's bladder and a deployment shape for passage of the device through the patient's urethra.

5. The use of claim 4, wherein the medicament contained in the housing is in a non-liquid form.

6. The use of claim 5, wherein the non-liquid form is selected from the group consisting of tablets, granules, semisolids, capsules, and combinations thereof.

7. The use of claim 1, wherein the medicament is to be delivered into the bladder from a coating substance applied to the bladder, which coating substance releases the medicament into the urine in the bladder over a sustained period.

8. The use of claim 7, wherein the coating substance comprises a mucoadhesive formulation.

9. The use of claim 1, wherein the locally administered comprises pumping a liquid form of the medicament into the bladder through a urethral catheter which is to be deployed into the bladder.

10. The use of any one of claims 1 to 9, wherein the medicament is to be locally administered into the patient's bladder from 1 mg/day to 100 mg/day of the gemcitabine for up to 7 days.

11. The use of any one of claims 1 to 9, wherein the medicament is to be locally administered into the patient's bladder from 20 mg/day to 300 mg/day of the gemcitabine for up to 7 days.

12. A drug delivery device comprising a medicament according to any one of the preceding claims, configured to locally administer the gemcitabine into the bladder continuously over a period of at least 6 hours, when the drug delivery device is to be inserted into the bladder.

13. Use of gemcitabine in the manufacture of a medicament for treatment of prostate cancer in a patient in need thereof, wherein the medicament is to be locally administered into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutic concentration of the gemcitabine in the prostate, and wherein the medicament is to be locally administered into the bladder continuously over a period of over 6 hours.

14. The use of claim 13, wherein at least a second therapeutic agent is to be administered to the patient.

15. The use of claim 14, wherein the second therapeutic agent is to be administered intravesically.

16. The use of claim 14 or 15, wherein the second therapeutic agent comprises a cytotoxic agent, an analgesic agent, an anti-inflammatory agent, or a combination thereof.

17. A medical device comprising:

a housing configured for intravesical insertion; and

a dosage form comprising gemcitabine,

wherein the housing holds the dosage form and is configured to release the gemcitabine into the bladder in an amount therapeutically effective for the treatment of prostate cancer, wherein the device is configured to release gemcitabine into the bladder at a mean average amount of from 1 mg/day to 300 mg/day of the gemcitabine, and wherein the device is configured to release gemcitabine into the bladder continuously over a period of over 6 hours.

18. The device of claim 17, wherein the gemcitabine contained in the housing is in a non-liquid form.

19. The device of claim 17, wherein the housing is elastically deformable between a retention shape configured to retain the device in a patient's bladder and a deployment shape for passage of the device through the patient's urethra.

20. The device of any one of claims 17 to 19, which is configured to release from 1 mg/day to 100 mg/day of the gemcitabine for up to 7 days.

21. The device of any one of claims 17 to 19, which is configured to release from 20 mg/day to 300 mg/day of the gemcitabine for up to 7 days.